China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...
The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...
The emergency response department of the National Health Commission (NHC) has released a notification signaling...
The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...
The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...
The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...
The State Administration for Market Regulation has released the latest version of the “Measures for...
China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...
China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...